Progenics Pharmaceuticals, Inc. (the “Company”) held its 2019 annual meeting of shareholders (the “Annual Meeting”) on July 11, 2019. Set forth below are the preliminary voting results as provided by First Coast Results, Inc., the independent Inspector of Election for the Annual Meeting (the “Inspector of Election”), for the proposals considered and voted upon at the Annual Meeting. Because of the contested nature of the Annual Meeting, there were no broker non-votes on any proposal submitted to a vote at the Annual Meeting. The results are preliminary and are subject to change based on certification of the final voting results by the Inspector of Election. The Company will file an amendment to this Current Report on Form 8-K to disclose the final, certified voting results after receiving such results from the Inspector of Election.

Proposal 1:     Election of Directors.

In accordance with the Company’s bylaws, Mr. Crowley and Mr. Kishbauch each submitted a contingent resignation on July 11, 2019, which will become effective only if the certification of the votes of the Annual Meeting confirms that they did not receive a majority of the votes cast and the Board of Directors (the “Board”) accepts the resignation.  As required under the Company’s bylaws, the Nominating and Corporate Governance Committee is considering these matters and will recommend to the Board the action to be taken with respect to the tendered contingent resignations.  The Board will determine whether to accept such resignations, or what other action should be taken, in accordance with the Company’s bylaws.

Proposal 2:     Ratification of Selection of Independent Registered Public Accounting Firm.

Proposal 3:     Advisory Vote on Executive Compensation.

About Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.